Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05594615 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05594615 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT05594615, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A Drug-Drug Interaction study to assess the effects of EDP-235 on the Pharmacokinetics and Safety of midazolam, caffeine and rosuvastatin.
Interventions
- DRUG Midazolam
- DRUG Rosuvastatin
- DRUG Caffeine
- DRUG EDP-235
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05594615
The ClinicalTrials.gov registry entry for NCT05594615 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Midazolam is the first listed.
NCT05594615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05594615 about?
NCT05594615 is a clinical study titled "Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects". A Drug-Drug Interaction study to assess the effects of EDP-235 on the Pharmacokinetics and Safety of midazolam, caffeine and rosuvastatin.
What is the current status of trial NCT05594615?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-10-06. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT05594615?
The interventions under investigation include: Midazolam (DRUG), Rosuvastatin (DRUG), Caffeine (DRUG), EDP-235 (DRUG).
Who is sponsoring clinical trial NCT05594615?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.